Transplant Immunopharmacology
Induction, maintenance, and rejection therapy in organ transplantation -- drug regimens, monitoring strategies, and long-term immunosuppression management.
## Phases of Transplant Immunosuppression
Transplant immunosuppression operates in three phases: **induction** (perioperative, highest immunosuppression intensity), **maintenance** (lifelong, lowest effective doses), and **rejection treatment** (pulse therapy for acute episodes). Each phase uses different drug combinations optimized for the risk-benefit balance at that time point.
## Induction Therapy
Induction agents provide intense immunosuppression during the early post-transplant period when rejection risk is highest. Two main strategies:
**Lymphocyte-depleting agents**: Anti-thymocyte globulin (ATG, rabbit or equine) depletes T cells through complement-mediated lysis and apoptosis. Used in high-immunologic-risk patients (sensitized, African American, re-transplants). Profound lymphopenia lasts weeks to months.
**Non-depleting agents**: Basiliximab (anti-CD25/IL-2R alpha) blocks IL-2 signaling on activated T cells without general lymphocyte depletion. Preferred in low-immunologic-risk patients. Two-dose regimen (day 0 and day 4).
Over 80% of US kidney transplant recipients receive induction therapy.
## Maintenance Immunosuppression
Standard triple therapy combines three drug classes targeting distinct pathways:
1. **Calcineurin inhibitor** (tacrolimus preferred over cyclosporine): Blocks T-cell activation via NFAT inhibition
2. **Antimetabolite** (mycophenolate preferred over azathioprine): Blocks lymphocyte proliferation via IMPDH inhibition
3. **Corticosteroids** (prednisone): Broad anti-inflammatory. Many centers pursue steroid minimization or withdrawal protocols after 3-6 months
Alternative regimens include belatacept-based (CNI-free, preserving renal function), mTOR inhibitor-based (CNI minimization), or steroid-free protocols. Drug selection depends on organ type, immunologic risk, comorbidities, and center experience.
## Therapeutic Drug Monitoring
Tacrolimus trough targets vary by time post-transplant and organ:
- **Kidney**: 8-12 ng/mL (month 1-3), 5-8 ng/mL (month 3-12), 4-6 ng/mL (after year 1)
- **Liver**: Generally lower targets; some centers use 4-8 ng/mL long-term
- **Heart**: Higher targets (10-15 ng/mL early) due to catastrophic consequences of rejection
Mycophenolate can be monitored by MPA AUC (target 30-60 mg*h/L) though routine TDM is not universally practiced.
## Acute Rejection Treatment
**Acute cellular rejection**: High-dose pulse methylprednisolone (500-1000 mg IV daily for 3 days). If steroid-resistant, ATG for 7-14 days.
**Antibody-mediated rejection**: Plasmapheresis (removes donor-specific antibodies), IVIG (immunomodulation), and rituximab (depletes B cells). Bortezomib (proteasome inhibitor) targets antibody-producing plasma cells in refractory cases.
## Long-Term Complications
Chronic immunosuppression carries cumulative risks: opportunistic infections (CMV, BK virus, Pneumocystis), malignancy (skin cancer 65x increased, PTLD from EBV), cardiovascular disease (hypertension, diabetes, dyslipidemia from CNIs and steroids), and chronic allograft injury. Prophylaxis protocols include valganciclovir (CMV), trimethoprim-sulfamethoxazole (Pneumocystis), and aggressive cardiovascular risk management.
## Key Takeaways
- Induction therapy (ATG or basiliximab) reduces early rejection risk during peak vulnerability
- Triple maintenance therapy targets three distinct immunological pathways simultaneously
- Tacrolimus trough monitoring guides dose adjustments through narrowing targets over time
- Long-term immunosuppression mandates vigilance for infections, malignancy, and cardiovascular disease